Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068597 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
A Phase 1 study of Multiple Myeloma and Acute Myeloid Leukemia, sponsored by CellCentric.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT04068597 is a Phase 1 study of Multiple Myeloma and Acute Myeloid Leukemia that is actively recruiting participants, run by CellCentric. The registered enrollment target is 250 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04068597, a Phase 1 study of Multiple Myeloma and Acute Myeloid Leukemia, is actively recruiting participants, sponsored by CellCentric.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG CCS1477
Study Locations (20)
Other
- Institute Bergonie - Bordeaux
- Gustave Roussy - Villejuif
- Hospital Germans Trias i Pujol/ ICO Badalona - Badalona
- University Hospital Vall D'Hebron - Barcelona
- Hospital Clínic de Barcelona - Barcelona
- ICO L'Hospitalet (Instituto Catalán de Oncología) - Barcelona
- Hospital Universitario de La Princesa - Madrid
- Hospital Universitario Gregorio Marañón - Madrid
- Hospital Infanta Leonor - Madrid
- Hospital Universitario Ramón y Cajal - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- CIOCC Hospital Universitario HM Sanchinarro - Madrid
- Universidad de Navarra - Pamplona
- Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana - Valencia
Nebraska
- Nebraska Cancer Specialists - Omaha
- University of Nebraska Medical Center - Omaha
Georgia
- Emory Winship Cancer Institute - Atlanta
Indiana
- Community Health Network - Indianapolis
Maryland
- The Center for Cancer and Blood Disorders (CCBD) - Bethesda
Pennsylvania
- Penn Medicine - Abramson Cancer Center Perelman - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2019-08-09 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04068597
The ClinicalTrials.gov registry entry for NCT04068597 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The listed sponsor is CellCentric, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.
NCT04068597 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Nebraska, Georgia.
Frequently Asked Questions
What is clinical trial NCT04068597 about?
NCT04068597 is a clinical study titled "Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies". A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
What is the current status of trial NCT04068597?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2019-08-09. Estimated completion is 2027-03-31.
What conditions does trial NCT04068597 study?
This clinical trial studies the following conditions: Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Higher-risk Myelodysplastic Syndrome.
What interventions are being tested in trial NCT04068597?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG), CCS1477 (DRUG).
Who is sponsoring clinical trial NCT04068597?
This trial is sponsored by CellCentric, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04068597 being conducted?
This trial has 20 study locations across Georgia, Indiana, Maryland, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.